DDX3X and B-cell non-Hodgkin lymphoma: In contrast to other mutations, for example in TP53, which accelerate lymphomagenesis in a c-MYC transgenic mouse model when deleted, the complete abrogation of DDX3X is incompatible with the emergence of B-cell lymphoma, excluding a role as a tumor suppressor at least in mice, whereas experiments with human GC cells show the opposite.